Table 2.
Clinical Trials of TLP and its Derivatives in Anticancer Research
| Studies | Ref. 79 | NCT01927965* | NCT03129139* | NCT03117920* |
|---|---|---|---|---|
| Type | Phase I (completed) | Phase I (completed) | Phase I (recruiting) | Phase II (recruiting) |
| Targeted enrolment | 20 | 45 | 54 | 35 |
| Tumor type | Advanced solid tumors | Advanced gastrointestinal tumors | Advanced cancer, gastric cancer, breast cancer, pancreatic cancer, prostate cancer metastatic, colorectal cancer, solid tumor, solid carcinoma, solid carcinoma of stomach, cancer of stomach | Pancreatic cancer |
| Interventions | Drug: F60008 | Drug: Minnelide™ 001 | Drug: Minnelide™ capsules | Drug: Minnelide |
| Major findings/purpose | F60008 cannot be considered the optimal derivative of triptolide | Determined the maximum tolerated dose (MTD), the dose-limiting toxicities (DLT), and the recommended dose for future phase 2 protocol | Research on safety, pharmacokinetics, and pharmacodynamics | To investigate whether it can slow tumor growth in patients with unresponsive pancreatic cancer |
| Year of registration | – | 2013 | 2017 | 2017 |
*
Further information can be found at http://clinicaltrials.gov